Sophia Zoungas
Monash University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sophia Zoungas as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:12 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT05586750 · Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging SubstudyMonash University · active not recruiting · Dementia, Mixed, Dementia, Vascular, Dementia of Alzheimer Type · principal investigator
- N/ANCT04536870 · Statins in Reducing Events in the Elderly (STAREE) Heart Sub-studyMonash University · active not recruiting · Heart Failure, Atrial Fibrillation, Healthy Ageing · study chair
- Ph4NCT02099123 · A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)Monash University · active not recruiting · Independent Living, Disability Free Survival, Elderly · principal investigator
- N/ANCT01944618 · forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)AstraZeneca · terminated · Type 2 Diabetes · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:12 UTC. The ranking covers the 200 most relevant of 80 PubMed records, and a shared surname and initials can bring in a namesake. All 80 on PubMed
- Severe hypoglycemia and risks of vascular events and death.N Engl J Med · 20101,158 citationsRCR 32.5
- Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.N Engl J Med · 2014453 citationsRCR 14.4
- Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes.Diabetologia · 2014382 citationsRCR 14.0
- Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.Diabetes Care · 2014287 citationsRCR 9.7
- Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds.Diabetologia · 2012250 citationsRCR 7.8
- Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.Kidney Int · 2013229 citationsRCR 7.3
- Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus.Circulation · 2016221 citationsRCR 8.6
- 204 citationsRCR 5.4
- 185 citationsRCR 6.1
- Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.J Am Coll Cardiol · 2006178 citationsRCR 4.6